专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007024825A3 IMMUNOAFFINITY SEPARATION AND ANALYSIS COMPOSITIONS AND METHODS 审中-公开
公开(公告)号：WO2007024825A3
公开(公告)日：2007-03-01
申请号：PCT/US2006/032712
申请日：2006-08-23
申请人： GENWAY BIOTECH, INC. , FANG, Xiangming , HUANG, Lei , ZHANG, Wei-Wei
发明人： FANG, Xiangming , HUANG, Lei , ZHANG, Wei-Wei
IPC分类号： G01N33/52 , C07K16/06
摘要： The present invention provides compositions and methods for immunoafflnity separation of targets from mixtures for enrichment, identification, quantification, and analysis. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use. Further disclosed are systems and methods for fractionating or enrichment a mixture of biological materials in an automated multiplex and high-throughput platform or system.

2. 发明申请

WO2005058950A3 METHODS FOR GENERATING IMMUNITY TO ANTIGEN 审中-公开
公开(公告)号：WO2005058950A3
公开(公告)日：2005-06-30
申请号：PCT/US2004/041690
申请日：2004-12-10
申请人： SIDNEY KIMMEL CANCER CENTER , DEISSEROTH, Albert , TANG, Yucheng , ZHANG, Wei-Wei , FANG, Xiang-Ming
发明人： DEISSEROTH, Albert , TANG, Yucheng , ZHANG, Wei-Wei , FANG, Xiang-Ming
IPC分类号： C07K14/705
摘要： Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

3. 发明申请

WO0231168A3 MINIMAL ADENOVIRAL VECTOR AND RECOMBINANT VACCINES BASED THEREON 审中-公开
标题翻译：最小的腺病毒和基于其的重组疫苗
公开(公告)号：WO0231168A3
公开(公告)日：2003-04-17
申请号：PCT/US0131842
申请日：2001-10-10
申请人： GENSTAR THERAPEUTICS , FANG XIANGMING , GALLICHAN SCOTT , ZHANG WEI-WEI , WONG-STAAL FLOSSIE , SAUTER SYBILLE
发明人： FANG XIANGMING , GALLICHAN SCOTT , ZHANG WEI-WEI , WONG-STAAL FLOSSIE , SAUTER SYBILLE
IPC分类号： A01K67/027 , C07K14/025 , C07K14/16 , C12N15/861 , A61K39/12 , A61K39/21 , C07K14/535
CPC分类号： A01K67/0275 , A01K2217/05 , A61K2039/525 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/20022 , C12N2710/20034 , C12N2740/16134 , C12N2740/16234 , C12N2740/16334 , C12N2800/108 , C12N2800/30 , C12N2830/003 , C12N2830/008 , C12N2830/38 , C12N2830/85 , C12N2840/20 , C12N2840/203
摘要： This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the AD vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation of propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line. This invention further comprises minimal adenoviral vectors for use in the treatment or prevention of disease or other medical conditions, methodologies for generating such vectors and animal test systems in vivo evaluation such Ad vectors. More specifically, this invention describes HIV and/or HPV Ad vectors that contain minimal cis-elements of the AD genome and comprise HIV and/or HPV nucleic acid sequence with other supporting and/or complementing nucleic acid elements up to about 36 kb to bout 38 kb. The HIV and/or HPV minimal Ad may be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also discloses designs and methods for testing such minimal AD vectors in vivo.
摘要翻译：本发明涉及腺病毒（Ad）载体及其在遗传医学领域中的应用，包括但不限于基因疫苗接种，基因转移，基因治疗等。更具体地说，本发明涉及携带Ad基因组的最小顺式元件（最小Ad载体）的AD载体，并且能够递送约36kb至约38kb的异源DNA。最小Ad载体的繁殖的产生需要在Ad辅助细胞系中进行包装减毒和复制缺陷型辅助Ad（helper）的互补。本发明进一步包括用于治疗或预防疾病或其它医学病症的最小腺病毒载体，用于产生这种载体的方法和动物试验系统体内评价这样的Ad载体。更具体地，本发明描述了含有AD基因组的最小顺式元件的HIV和/或HPV Ad载体，并且包含HIV和/或HPV核酸序列，其具有高达约36kb的其它支持和/或补体核酸元件 38 kb。 HIV和/或HPV最小Ad可以通过包装减毒的辅助Ad和辅助细胞系的帮助产生并优先扩增。本发明还公开了在体内测试这样的最小AD载体的设计和方法。

4. 发明申请

WO2007024825A2 IMMUNOAFFINITY SEPARATION AND ANALYSIS COMPOSITIONS AND METHODS 审中-公开
标题翻译：免疫分离和分析组合物和方法
公开(公告)号：WO2007024825A2
公开(公告)日：2007-03-01
申请号：PCT/US2006032712
申请日：2006-08-23
申请人： GENWAY BIOTECH INC , FANG XIANGMING , HUANG LEI , ZHANG WEI-WEI
发明人： FANG XIANGMING , HUANG LEI , ZHANG WEI-WEI
IPC分类号： G01N33/53 , C12M1/34
CPC分类号： C07K1/22 , G01N33/543
摘要： The present invention provides compositions and methods for immunoafflnity separation of targets from mixtures for enrichment, identification, quantification, and analysis. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use. Further disclosed are systems and methods for fractionating or enrichment a mixture of biological materials in an automated multiplex and high-throughput platform or system.
摘要翻译：本发明提供了用于浓缩，鉴定，定量和分析的目标与混合物的免疫亲和分离的组合物和方法。特别地，公开了与固体支持物及其使用方法偶联的禽IgY抗体。进一步公开的是用于在自动多路复用和高通量平台或系统中分馏或富集生物材料的混合物的系统和方法。

5. 发明申请

WO2005049653A1 AFFINITY SEPARATION COMPOSITION AND METHOD 审中-公开
标题翻译： AFFINITY分离组合物和方法
公开(公告)号：WO2005049653A1
公开(公告)日：2005-06-02
申请号：PCT/US2004/022786
申请日：2004-07-14
申请人： GENWAY BIOTECH, INC. , FANG, Xiangming , HUANG, Lei , LIN, Ping , FEITELSON, Jerald, S. , ZHANG, Wei-Wei
发明人： FANG, Xiangming , HUANG, Lei , LIN, Ping , FEITELSON, Jerald, S. , ZHANG, Wei-Wei
IPC分类号： C07K16/02
CPC分类号： C07K16/42 , C07K1/22 , C07K16/18 , C07K16/4283 , C07K2317/23
摘要： Affinity separation compositions and methods are disclosed for separating targets from complex mixtures. Affinity reagents are bound to a solid support oriented in a manner to facilitate the activity of the affinity reagents which are capable of binding specific targets by affinity recognition. Affinity reagents include IgY antibodies, proteins, peptides, nucleotides and polymers. Targets include proteins, protein-protein complexes, protein-nucleotide complexes, nucleotides, cells and subcellular organelles.
摘要翻译：公开了亲和力分离组合物和方法用于从复杂混合物中分离靶物。亲和试剂结合固体支持物，其方式是促进通过亲和力识别能够结合特异性靶标的亲和试剂的活性。亲和试剂包括IgY抗体，蛋白质，肽，核苷酸和聚合物。目标包括蛋白质，蛋白质 - 蛋白质复合物，蛋白质 - 核苷酸复合物，核苷酸，细胞和亚细胞器。

6. 发明申请

WO2002085287A2 MINIMAL ADENOVIRAL VECTORS FOR IMMUNIZATION 审中-公开
标题翻译：最小的ADENOVIRAL矢量免疫
公开(公告)号：WO2002085287A2
公开(公告)日：2002-10-31
申请号：PCT/US2002/012237
申请日：2002-04-18
申请人： GENSTAR THERAPEUTICS CORP. , ZHANG, Wei-Wei , JOSEPHS, Steven , BALAGUE, Cristina , FANG, Xiangming
发明人： ZHANG, Wei-Wei , JOSEPHS, Steven , BALAGUE, Cristina , FANG, Xiangming
IPC分类号： A61K
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/072 , A01K2217/075 , A01K2217/20 , A01K2227/105 , A01K2267/01 , A01K2267/0306 , A01K2267/0331 , A61K38/37 , A61K48/00 , C12N15/8509 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2800/108 , C12N2800/30 , C12N2830/006 , C12N2830/008 , C12N2830/42 , C12N2830/85 , C12N2840/20 , C12N2840/203
摘要： The present invention provides a method for treating a disorder such as hemophilia. A method of treating hemophilia in a mammal by administering recombinant virus virions comprising a nucleotide sequence having an adenoviral inverted terminal repeat fusion sequence, a packaging signal, a transcriptional control region, and a nucleic acid encoding a therapeutic protein such as FVIII. In addition, the DNA molecule does not encode an adenoviral protein. It is preferred that the virions be administered to the mammal under conditions that result in the expression of the therapeutic protein at a level that provides a therapeutic effect in said mammal.
摘要翻译：本发明提供了治疗诸如血友病的病症的方法。通过施用包含具有腺病毒反向末端重复融合序列，包装信号，转录控制区和编码治疗性蛋白如FVIII的核酸的核苷酸序列的重组病毒颗粒来治疗哺乳动物血友病的方法。此外，DNA分子不编码腺病毒蛋白。优选地，在导致治疗性蛋白质表达在所述哺乳动物中提供治疗效果的水平的条件下，向哺乳动物施用病毒粒子。

7. 发明申请

WO2005058950A2 METHODS FOR GENERATING IMMUNITY TO ANTIGEN 审中-公开
标题翻译：用于产生抗原免疫的方法
公开(公告)号：WO2005058950A2
公开(公告)日：2005-06-30
申请号：PCT/US2004041690
申请日：2004-12-10
申请人： SIDNEY KIMMEL CANCER CT , DIESSEROTH ALBERT , TANG YUCHENG , ZHANG WEI-WEI , FANG XIANG-MING
发明人： DIESSEROTH ALBERT , TANG YUCHENG , ZHANG WEI-WEI , FANG XIANG-MING
IPC分类号： C07K14/705 , C07K14/47
CPC分类号： C07K14/70575 , C07K2319/40
摘要： Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.
摘要翻译：提供了产生对抗原的免疫应答的方法。该方法包括通过施用编码抗原的表达载体来引发个体。载体包含编码可分泌融合蛋白的转录单元，含有抗原和CD40配体的融合蛋白。使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。本发明的方法可用于产生针对表达肿瘤抗原如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答，并产生针对感染因子的免疫应答。还提供了同时产生表达载体和融合蛋白的方法。

8. 发明申请

WO2002085287A3 MINIMAL ADENOVIRAL VECTORS FOR IMMUNIZATION 审中-公开
公开(公告)号：WO2002085287A3
公开(公告)日：2002-10-31
申请号：PCT/US2002/012237
申请日：2002-04-18
申请人： GENSTAR THERAPEUTICS CORP. , ZHANG, Wei-Wei , JOSEPHS, Steven , BALAGUE, Cristina , FANG, Xiangming
发明人： ZHANG, Wei-Wei , JOSEPHS, Steven , BALAGUE, Cristina , FANG, Xiangming
IPC分类号： C12N15/00
摘要： The present invention provides a method for treating a disorder such as hemophilia. A method of treating hemophilia in a mammal by administering recombinant virus virions comprising a nucleotide sequence having an adenoviral inverted terminal repeat fusion sequence, a packaging signal, a transcriptional control region, and a nucleic acid encoding a therapeutic protein such as FVIII. In addition, the DNA molecule does not encode an adenoviral protein. It is preferred that the virions be administered to the mammal under conditions that result in the expression of the therapeutic protein at a level that provides a therapeutic effect in said mammal.

9. 发明申请

WO9745550A3 MINI-ADENOVIRAL VECTOR 审中-公开
标题翻译：微型腺病毒载体
公开(公告)号：WO9745550A3
公开(公告)日：1998-04-09
申请号：PCT/US9710218
申请日：1997-05-30
申请人： BAXTER INT , ZHANG WEI WEI , ALEMANY RAMON , DAI YIFAN , JOSEPHS STEVEN , BALAGUE CRISTINA , AYARES DAVID , SCHNEIDERMAN RICHARD
发明人： ZHANG WEI-WEI , ALEMANY RAMON , DAI YIFAN , JOSEPHS STEVEN , BALAGUE CRISTINA , AYARES DAVID , SCHNEIDERMAN RICHARD
IPC分类号： A01K67/027 , A61K31/711 , A61K35/76 , A61K38/00 , A61K38/43 , A61K48/00 , A61P7/04 , C07K14/755 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/34 , C12N15/85 , C12N15/861 , C12Q1/02 , C12Q1/68 , G01N21/78 , G01N33/53 , G01N33/68 , C12N15/86 , C12N7/01
CPC分类号： C12N15/8509 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2217/20 , A01K2267/0306 , A61K38/00 , A61K48/00 , C07K14/755 , C12N15/86 , C12N2710/10343 , C12N2800/108 , C12N2800/30 , C12N2810/859 , C12N2830/003 , C12N2830/008 , C12N2830/38 , C12N2830/85 , C12N2840/20 , C12N2840/203 , C12N2840/206
摘要： This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including gene transfer, gene therapy, and gene vaccination. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (mini-Ad vector) and are capable of delivering transgenes and/or heterologous DNA up to 36 kb. The generation and propagation of the mini-Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line. This invention further comprises a methodology for generating a mini-adenoviral (mini-Ad) vector for use in gene therapy of hemophilia and animal test systems for in vivo evaluation of the Ad vectors. More specifically, this invention describes factor VIII (FVIII) Ad vectors that only contain minimal cis-element of the Ad genome (so-called mini-Ad) and comprise a human FVIII cDNA with other supporting DNA elements up to 36 kb. The FVIII mini-Ad can be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also reports designs and methods for producing transgenic mouse models that can be used for in vivo testing the mini-Ad.

10. 发明申请

WO0208436A3 MINI-ADENOVIRAL VECTOR SYSTEM FOR VACCINATION 审中-公开
标题翻译：用于疫苗接种的微型腺病毒载体系统
公开(公告)号：WO0208436A3
公开(公告)日：2003-02-27
申请号：PCT/US0123005
申请日：2001-07-20
申请人： GENSTAR THERAPEUTICS CORP , ZHANG WEI-WEI , ALEMANY RAMON , DAI YIFAN , JOSEPHS STEVEN , BALAGUE CRISTINA , AYARES DAVID , SCHNEIDERMAN RICHARD
发明人： ZHANG WEI-WEI , ALEMANY RAMON , DAI YIFAN , JOSEPHS STEVEN , BALAGUE CRISTINA , AYARES DAVID , SCHNEIDERMAN RICHARD
IPC分类号： A61K39/00 , A61K48/00 , C07K14/755 , C12N15/12 , C12N15/16 , C12N15/19 , C12N15/861
CPC分类号： C12N15/86 , A61K39/00 , A61K48/00 , A61K2039/5256 , C07K14/755 , C12N2710/10343 , C12N2800/108 , C12N2800/30 , C12N2810/859 , C12N2830/008 , C12N2830/42 , C12N2830/85 , C12N2840/203 , C12N2840/206
摘要： The principle of this invention is to produce mini-Ad vectors using packaging-attenuated and replication-defective helper Ad and an E1-complementing Ad helper cell line. Since the essential cis-acting elements for Ad DNA replication and packaging are located at the ends of the viral genome (ITRs plus the packaging signal, less than 1 kb), the backbone of the mini-Ad vectors is trimmed down to contain only the essential cis -elements. The remainder of the Ad genome is to be replaced by non-viral DNA for gene transfer, retention, and expression. The capacity of the mini-Ad vectors may be up to 36 kb. The viral proteins required for DNA replication and encapsidation of the mini-Ad vectors are designed to be provided in trans from the helper Ad ( trans )-complementation) and the helper cell line. In order to generate relatively pure preparations of the mini-Ad virions, packaging of the helper Ad genome is controlled by selective attenuation of the packaging signal while that of the mini-Ad vector genome proceeds normally. In the absence of mini-Ad vector genome, the helper Ad does replicate and is propagated in an inefficient manner. In this system, the Ad helper cell line is necessary for the E1-complementation of the helper virus and may also provide other functions for packaging attenuation of the helper viral genome and enhancement of mini-Ad vector replication. If the preparation of mini-Ad vectors is not sufficiently pure, biochemical or other physical methods will be utilized to achieve further purification.
摘要翻译：本发明的原理是使用包装减毒和复制缺陷型辅助Ad和E1互补的Ad辅助细胞系来生产小型Ad载体。由于用于Ad DNA复制和包装的基本顺式作用元件位于病毒基因组的末端（ITRs加上包装信号小于1kb），微型Ad载体的主链被修剪成仅包含重要的顺式元件。 Ad基因组的其余部分将被用于基因转移，保留和表达的非病毒DNA替代。小型Ad载体的容量可达36kb。设计mini-Ad载体的DNA复制和壳化所需的病毒蛋白质是从辅助Ad（反式） - 互补）和辅助细胞系反向提供的。为了产生相对纯的微型Ad病毒粒子的制剂，通过选择性衰减包装信号来控制辅助Ad基因组的包装，而迷你Ad载体基因组的包装正常进行。在没有mini-Ad载体基因组的情况下，辅助Ad不会复制并以低效的方式传播。在该系统中，Ad辅助细胞系对辅助病毒的E1互补是必需的，并且还可以提供用于包装辅助病毒基因组衰减和增强小型Ad载体复制的其他功能。如果微型Ad载体的制备不够纯，将采用生物化学或其他物理方法来进一步纯化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式